Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study) Meeting Abstract


Authors: Segal, N. H.; Reidy-Lagunes, D.; Capanu, M.; Kemeny, N.; Chung, K.; Kelsen, D.; Hollywood, E.; Goodman-Davis, N.; Saltz, L. B.
Abstract Title: Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study)
Meeting Title: 45th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 27
Issue: 15 Suppl.
Meeting Dates: 2009 May 29-Jun 2
Meeting Location: Orlando, FL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2009-05-20
Start Page: 189s
Language: English
ACCESSION: WOS:000276606601029
PROVIDER: wos
Notes: Meeting Abstract: 4087 -- Source: Wos